Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies
Metastatic Cancer

Interventions

DRUG: INCAGN01876
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Incyte Biosciences International Sàrl